NeOnc Technologies Holdings, Inc. NTHI 深 滬
已收盤 12-24 16:00:00 美东时间
8.35
-0.010
-0.12%
華盛通- 最 高8.54
- 今 開8.37
- 成交量 1.60万股
- 最 低 8.22
- 昨 收 8.36
- 總市值 1.63亿
- 52周最高 25.00
- 市盈率 靜 --
- 換手率 0.08%
- 52周最低 3.20
- 委 比 -75.95%
- 總股本 1947.43万
- 歷史最高 25.00
- 量 比 0.17
- 振 幅 3.83%
- 歷史最低 3.20
- 每 手 1
- 風險率 2.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NeOnc Technologies Announces Updated Results From Phase 1/2a And Compassionate-Use Experience Of NEO100; Says Updated Results Demonstrate Radiographic Remission In 6 Of 25 Patients
Updated results demonstrate that treatment with intranasally delivered NEO100 has resulted in significant radiographic remission in 6 of 25 patients (24%), representing 3X increase over the 8% response rates typically
12-15 22:04
NeOnc Announces Updated Clinical Results From Current Phase 1/2a And Compassionate Care Studies Involving Cohort Of 24 Patients With Recurrent WHO Grade III/IV IDH1–Mutant Astrocytoma Treated With NEO100
NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi–Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers today announced updated
11-12 21:03
His Highness Sheikh Nahyan bin Zayed Al Nahyan Assumes Executive Chairmanship of NeOnc Technologies' Subsidiary, NuroMENA, Pioneering UAE-US Partnership in Brain Cancer Treatment
NeOnc Technologies Holdings, Inc. (NeOnc) announced that His Highness Sheikh Nahyan bin Zayed Al Nahyan will become the Executive Chairman of NuroMENA Holdings Ltd., the Middle East subsidiary of NeOnc, which focuses on developing treatments for brain cancer and other CNS malignancies. This partnership underscores the UAE's commitment to addressing global health challenges and aligns with Sheikh Nahyan's humanitarian vision. NeOnc's NEO™ platform...
10-28 13:00
NeOnc Technologies Announces $50M Partnership with Quazar
An update from NeOnc Technologies Holdings, Inc. ( ($NTHI) ) is now available. ...
10-11 05:34
NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42’s IROS and Expands Board of Directors
NeOnc Technologies Holdings, Inc. has announced two strategic developments: its subsidiary NuroMENA Holdings Ltd. signed a Master Services Agreement (MSA) with Insights Research Organization and Solutions (IROS), a UAE-based CRO part of M42, to leverage advanced healthcare infrastructure for clinical trials, enhancing cancer therapy development. Additionally, NuroMENA's Board of Directors has expanded with key partners from Quazar Investment, rei...
10-09 13:00
NeOnc Technologies and Quazar Investment Set to Close $50 Million Strategic Partnership by October 23rd Following Final UAE Tax Approvals
NeOnc Technologies Holdings, Inc. (NTHI) announced the finalization of its $50 million strategic partnership with Quazar Investment, following the receipt of all necessary tax identification and regulatory approvals from the UAE. The closing is mandated to occur no later than October 23, 2025. The partnership focuses on launching and scaling clinical trials, regulatory filings, and infrastructure development across the UAE and MENA region through...
10-06 13:00
NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board
NeOnc Technologies Holdings, Inc. has appointed Dr. David M. Ashley to its Scientific Advisory Board. As a leading neuro-oncologist and director of Duke University's Preston Robert Tisch Brain Tumor Center, Dr. Ashley brings extensive expertise in brain tumor immunology and epigenetics to strengthen NeOnc's pipeline, including its Phase II candidates NEO100™ and NEO212™. His leadership and research will guide NeOnc's mission to develop life-chang...
10-02 13:00
NeOnc Technologies Welcomes Dr. Alexandra M. Miller, Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health’s Perlmutter Cancer Center, to Its Scientific Advisory Board
NeOnc Technologies Holdings, Inc. has appointed Dr. Alexandra M. Miller to its scientific advisory board. Dr. Miller, a leading expert in neuro-oncology, is known for her work in liquid biopsy assays for CNS tumors and her expertise in using cerebrospinal fluid for diagnosing and monitoring gliomas. Her insights will support the advancement of NeOnc's clinical trials for NEO100™ and NEO212™. NeOnc is expanding its global trial network, with new s...
10-01 13:00
NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board
NeOnc Technologies Holdings, Inc. (NTHI) has appointed Dr. Henry S. Friedman to its scientific advisory board. Dr. Friedman, a leading neuro-oncologist at Duke University, brings extensive expertise in developing therapies for central nervous system cancers. His加入将进一步推进NeOnc的临床试验项目，包括NEO100™和NEO212™，为脑癌患者带来希望。公司致力于突破血脑屏障挑战，推动创新治疗方案的研发。
09-29 13:00
